Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

9MFG

Complex of IL23 receptor and VHH

Summary for 9MFG
Entry DOI10.2210/pdb9mfg/pdb
Related9MDZ
DescriptorInterleukin-23 receptor, GLYCEROL, SULFATE ION, ... (12 entities in total)
Functional Keywordsimmunology, ibd, inflammatory bowel disease, immune system
Biological sourceHomo sapiens (human)
More
Total number of polymer chains8
Total formula weight202838.28
Authors
Kiefer, J.R.,Wallweber, H.A.,Koerber, J.T.,Ota, N.,Davies, C. (deposition date: 2024-12-09, release date: 2025-05-21, Last modification date: 2025-06-11)
Primary citationOta, N.,Davies, C.W.,Kang, J.,Yan, D.,Scherl, A.,Wong, A.,Cook, R.,Tao, X.,Dunlap, D.,Klabunde, S.,Mantik, P.,Mohanan, V.,Lin, W.,McBride, J.,Sadekar, S.,Storek, K.M.,Lupardus, P.,Ye, Z.,Ackerly Wallweber, H.,Kiefer, J.R.,Xu, M.,Chan, P.,Nagapudi, K.,Yi, T.,Koerber, J.T.
Engineering a protease-stable, oral single-domain antibody to inhibit IL-23 signaling.
Proc.Natl.Acad.Sci.USA, 122:e2501635122-e2501635122, 2025
Cited by
PubMed Abstract: Interleukin (IL)-23 is a validated therapeutic target in inflammatory bowel disease. While antibodies targeting IL23 demonstrate clinical efficacy, they face challenges such as high costs, safety risks, and the necessity of parenteral administration. Here, we present a workflow to simultaneously enhance the affinity and protease stability of an inhibitory anti-IL23R VHH for oral use. Cocrystal structure analysis reveals that the anti-IL23R VHH employs both CDR and framework residues to achieve picomolar affinity for IL23R. The engineered VHH remains stable for over 8 h in intestinal fluid and 24 h in fecal samples. Oral administration of this VHH achieves deep pathway inhibition in a murine colitis model. Furthermore, a single pill provides sustained IL23R inhibition in nonhuman primate blood for over 24 h. With high potency, gut stability, high production yield, and favorable drug-like properties, oral VHHs offer a promising approach for inflammatory bowel diseases.
PubMed: 40434646
DOI: 10.1073/pnas.2501635122
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.85 Å)
Structure validation

237735

数据于2025-06-18公开中

PDB statisticsPDBj update infoContact PDBjnumon